Explore a decade of accomplishments, including going public in 1992, acquiring nine companies, reaching $1.8 billion in revenue, and establishing ourselves as a leader in the treatment of cardiology and vascular diseases. Explore a decade of accomplishments, including going public in 1992, acquiring nine companies, reaching $1.8 billion in revenue, and establishing ourselves as a leader in the treatment of cardiology and vascular diseases.

   


Growth and Acquisitions

  

By 1997, Boston Scientific had acquired nine more companies, posted $1.8 billion in revenue and asserted itself as a leader in coronary angioplasty and nonvascular therapy. | Boston Scientific went public on May 19, 1992 and continued to seek targeted leadership in its specialties through acquisitions and strategic alliances. By 1997, Boston Scientific had acquired nine more companies, posted $1.8 billion in revenue and asserted itself as a leader in coronary angioplasty and nonvascular therapy. | Boston Scientific went public on May 19, 1992 and continued to seek targeted leadership in its specialties through acquisitions and strategic alliances. Top